Blinatumomab, a CD19-binding bispecific Ab, and Inotuzumab ozogamicin, an ADC that binds to CD22, received FDA- and EMA- approval for the treatment of relapsed or refractory B-ALL. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.